Clinical trials: Cephalalgia
Migraine Headache, Episodic
A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
This is a randomized, blinded study designed to assess the efficacy of a portable, non-invasive neuromodulation system for the treatment of episodic migraine headaches.
- Trial name
- NCT01899040
- Testing
- neuromodulation for episodic migraine headache
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 100 people
- Sponsor
- Scion NeuroStim
Migraine Disorders, Headache Disorders
Topical Bimatoprost in the Treatment of Migraine
The study is to assess the effectiveness of topically applied bimatoprost in reducing migraine headache frequency, severity, and duration. It will also assess the effect of topical bimatoprost on quality of life.
- Trial name
- NCT03419715
- Testing
- Bimatoprost Topical Solution, Control
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Manistee Partners
Migraine
A Controlled Trial of Erenumab in Migraine Prevention
The purpose of this study was to assess the efficacy and safety of erenumab for prevention of migraine in Japanese adults with episodic migraine (EM) and chronic migraine (CM).
- Trial name
- NCT03812224
- Testing
- Erenumab
- Where
- 41 sites in Japan
- Volunteers
- 261 people
- Sponsor
- Amgen
Chronic Cluster Headache
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
The purpose of the current study is to evaluate the efficacy and safety of Fremanezumab (TEV-48125), in the prevention of CCH in adult participants.
- Trial name
- NCT02964338
- Testing
- Fremanezumab
- Where
- 83 sites in United States, Australia and 10 more
- Volunteers
- 259 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Cluster Headache
Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
The primary objectives of the Registry are to: 1. Monitor the transfer of the ATI Neurostimulation System and its safety/clinical performance to a larger number of centers in the post market phase and 2.
- Trial name
- NCT01677026
- Where
- 11 sites in Denmark, Germany
- Volunteers
- 150 people
- Sponsor
- Autonomic Technologies, Inc.
Migraine
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.
- Trial name
- STRIVE (NCT02456740)
- Testing
- Erenumab
- Where
- 129 sites in United States, Austria and 11 more
- Volunteers
- 955 people
- Sponsor
- Amgen
Migraine
Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.
This was a retrospective registry-based study utilizing data collected in association with clinical care of patients. All data was stored in electronic health records at Terveystalo data base, and no patients were contacted for…
- Trial name
- NCT05375097
- Testing
- Erenumab
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Migraine, Migraine Disorders
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
This is a 128-week open-label study to assess the long-term safety and tolerabilty of the monoclonal antibody erenumab in migraine patients.
- Conditions
- Migraine, Migraine Disorders, Migraine Headache
- Trial name
- APOLLON (NCT04084314)
- Testing
- Erenumab
- Where
- 75 sites in Germany
- Volunteers
- 701 people
- Sponsor
- Novartis Pharmaceuticals
Migraine
The Effect of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine
This multi-center, double-blind, placebo-controlled, parallel group trial carbon dioxide in the treatment of moderate to severe migraine.
- Trial name
- NCT01253915
- Testing
- Nasal Carbon Dioxide
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Capnia, Inc.
Migraine
Chordate System Prophylactic Migraine Clinical Investigation
The purpose of this pilot study is to evaluate the performance of the Chordate System, in terms of the prophylactic effect and tolerability of treatment in patients diagnosed with migraine.
- Trial name
- NCT02243865
- Testing
- Chordate System S200 + CT100 (active treatment)
- Where
- 4 sites in Sweden
- Volunteers
- 87 people
- Sponsor
- Chordate Medical
Migraine
Acute Treatment Trial in Adult Subjects With Migraines
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
- Trial name
- NCT03872453
- Testing
- Zavegepant, Intranasal Aptar Pharma Unit Dose System
- Where
- 82 sites in United States
- Volunteers
- 2,154 people
- Sponsor
- Pfizer
Intervention
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.
- Trial name
- NCT02991430
- Testing
- active neuromodulation for episodic migraine headache
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Scion NeuroStim
Migraine Disorders
A Study of Gastric Delay in Migraine Patients (3207-003)
A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.
- Trial name
- NCT00548353
- Testing
- MK3207
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack
The purpose of this research study is to evaluate an investigational auto-injector system for delivering sumatriptan under the skin for a single migraine attack.
- Trial name
- NCT00510419
- Testing
- "Investigational"Auto-injector (sumatriptan succinate)
- Where
- 10 sites in United States
- Volunteers
- 73 people
- Sponsor
- Pfizer
Migraine, Acute
Use Of SB-705498 In The Acute Treatment Of Migraine
Despite the success of the triptan class of drugs, approximately 60% of patients who take medication at the moderate to severe pain stage of acute migraine, still have pain of mild or greater degree at 2 hrs post dose.
- Trial name
- NCT00269022
- Testing
- SB-705498
- Where
- 4 sites in Australia, Canada and 2 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Migraine
Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine
The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.
- Trial name
- NCT01016834
- Testing
- Sumavel DosePro, Sumatriptan
- Where
- 21 sites in United States
- Volunteers
- 246 people
- Sponsor
- Zogenix, Inc.
Migraine
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants
This first in-human (FIH) study of UB-313, an anti-calcitonin gene-related peptide based immunotherapeutic candidate, is designed to assess the safety, tolerability, and immunogenicity of 4 selected UB-313 dose regimens in…
- Trial name
- NCT05477095
- Testing
- UB-313
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vaxxinity, Inc.
Migraine
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 (monthly TEV-48125 225 mg and TEV-48125 675 mg once over a period of 3 months) compared with placebo for preventive treatment in Episodic…
- Trial name
- NCT03303092
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 357 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Migraine Disorders
Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet
The study is designed to investigate the information on safety and efficacy of naratriptan tablets on Japanese subjects with migraine headache during Japanese post-marketing surveillance period.
- Trial name
- NCT01376193
- Testing
- Naratriptan
- Volunteers
- 500 people
- Sponsor
- GlaxoSmithKline
Migraine
Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition
The purpose of this study is to evaluate the pharmacokinetics (PK) of BMS-927711 during migraine and non-migraine condition.
- Trial name
- NCT01445067
- Testing
- BMS-927711 (CGRP Antagonist)
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Pfizer